logo
Is Metformin Used For Weight Loss? What You Need To Know

Is Metformin Used For Weight Loss? What You Need To Know

Forbes4 hours ago

Metformin is a first-line treatment for type 2 diabetes, approved by the U.S. Food and Drug Administration (FDA) to treat the condition in 1994. While not FDA-approved for weight management, metformin may play a valuable role when used in conjunction with other medications for individuals who have obesity. However, the potential for weight loss as a side effect of metformin use alone remains unclear.
Discover how metformin works and all that it treats, as well as its potential impact on weight loss, other side effects and safety.
'Metformin is a widely used, first-line medication for treating type 2 diabetes . It belongs to a class of drugs called biguanides,' says Hans J. Schmidt, M.D., chief of bariatric surgery and director of the Center for Weight Loss and Metabolic Health at Hackensack University Medical Center in New Jersey. It can be used alongside other medications, such as insulin, or on its own.
'It's typically recommended alongside lifestyle changes like diet and exercise, and is often the first medication doctors turn to because of its strong track record for safety, effectiveness and metabolic benefits,' adds Sam Setareh, M.D ., director of clinical cardiology at Beverly Hills Cardiovascular, attending cardiologist at Cedars Sinai Medical Center and Forbes Health Advisory Board member.
Metformin can be taken via mouth in the form of a tablet, extended-release tablet or liquid. The regular tablet is taken two to three times a day with meals, while the long-lasting, extended-release tablet is taken once daily in the evening with a meal. The liquid solution can be taken once or twice daily with meals. How Does Metformin Work?
'It works primarily by reducing glucose production in the liver. This is a major contributor to high blood sugar in people with type 2 diabetes,' explains Dr. Schmidt. Metformin helps to manage the amount of glucose in the blood, reducing how much glucose is absorbed from food and produced by the liver. 'Additionally, metformin improves insulin sensitivity, which helps the body's cells use insulin more effectively to absorb glucose from the bloodstream,' he adds.
'Unlike some diabetes drugs, it doesn't force the pancreas to produce more insulin, which means it carries a low risk of causing low blood sugar,' notes Dr. Setareh.
'Metformin is primarily used to treat type 2 diabetes. It helps manage blood sugar levels by reducing glucose production in the liver, improving insulin sensitivity, and slightly decreasing glucose absorption in the intestines,' says Dr. Schmidt. Note that this drug manages type 2 diabetes and does not cure it. Metformin should not be used to treat type 1 diabetes.
'I cannot stress enough that metformin is not a primary weight loss medication,' adds Dr. Schmidt. 'It's used to treat certain conditions that are associated with increased weight, like insulin resistance and polycystic ovary syndrome (PCOS). Patients may lose weight as their underlying condition improves. But it is not for the general population.' Does Metformin Help With Weight Loss?
Metformin is primarily a diabetes medication and not typically a first-line treatment for weight loss or prescribed solely for weight loss, according to Dr. Schmidt. 'Metformin can contribute to modest weight loss or help prevent weight gain, but it's not primarily a weight loss drug. While some people experience noticeable weight loss, others maintain their weight or even experience a slight weight gain,' he adds.
Metformin's effect on weight isn't yet fully understood, but it's thought to be related to decreased appetite, reduced glucose absorption in the gut and changes in how the body stores and uses fat, explains Dr. Schmidt. He adds that the impact on weight can largely vary, with some people noticing weight loss and others experiencing no change at all. 'The weight loss associated with metformin tends to plateau after a year or so. It's not a quick fix or a long-term solution for significant weight loss,' he says.
Metformin is most effective for weight management when used in conjunction with regular exercise and a healthy diet, says Dr. Schmidt. 'These lifestyle changes are crucial for achieving and maintaining a healthy weight.'
Ozempic is a brand-name form of semaglutide , a glucagon-like peptide-1 (GLP-1) receptor agonist. While Ozempic is FDA-approved to treat type 2 diabetes and reduce the risk of certain medical conditions or events, neither Ozempic nor metformin is FDA-approved for weight loss .
The two medications do have similarities: Both are prescription medications that can be used in the treatment of type 2 diabetes, help to reduce blood sugar levels and can be taken alongside additional diabetes medications, such as insulin, for better blood sugar control, according to Dr. Schmidt.
Both drugs have also shown benefits outside of blood sugar management. Metformin may have a positive impact on PCOS, with many studies showing it could be potentially useful in treating PCOS-related infertility.
However, when treating type 2 diabetes and lowering blood sugar, the two medications work through different mechanisms with differing characteristics. Metformin works by reducing glucose production in the liver and improving insulin sensitivity, whereas Ozempic mimics a natural hormone called GLP-1 , which increases insulin release when a person's blood sugar is high, suppresses glucagon secretion, slows stomach emptying and promotes a feeling of being full, according to Dr. Schmidt.
In January 2025, Ozempic was FDA-approved to reduce the risk of major cardiovascular events, such as stroke, in individuals with type 2 diabetes and known heart disease, as well as lower the risk of kidney failure, kidney disease worsening and death as a result of cardiovascular disease in those with type 2 diabetes and chronic kidney disease. While weight loss may also be a common side effect of using Ozempic, it is not FDA-approved for weight management.
Unlock Rapid Weight Loss
Take a 2-minute quiz for instant approval and access Semaglutide or Tirzepatide from U.S. pharmacies—no insurance, no waitlist, no hidden fees. Lose up to 1.5% body fat per week. Get Started
On Remedy Meds' Website
'Metformin is generally well-tolerated, but some people experience side effects, most commonly gastrointestinal issues,' says Dr. Schmidt. While these can improve over time or with dose adjustments, he notes the following to be potential side effects: Nausea
Stomach pain
Vomiting
Indigestion
Diarrhea
Metallic taste in the mouth
Loss of appetite
'Some people notice a metallic taste, and over long periods, metformin can lower vitamin B12 levels, which may lead to fatigue, numbness or other symptoms if not monitored,' explains Dr. Setareh. 'In rare cases, particularly in people with kidney or liver problems, there's a risk of lactic acidosis, a serious but uncommon complication. Metformin generally doesn't cause low blood sugar unless it's combined with other medications that do.'
'It's also crucial to remember that Metformin is a prescription medication and should only be used under the guidance of a healthcare professional. Never self-medicate,' adds Dr. Schmidt.
It's best to speak to your doctor before taking metformin to discuss all potential risks and side effects. Is Metformin Safe?
'Metformin is generally considered a safe medication when prescribed and monitored appropriately. It has a long history of use and a well-established safety profile. However, like all medications, speak to your doctor before taking it,' notes Dr. Schmidt.
Anyone taking the drug should follow their prescription label carefully and take the drug exactly as directed by their physician. Individuals should continue taking the drug even if they feel well.
If you're thinking about metformin for weight management, it's essential to discuss this with your doctor, who can assess your situation, determine if it's appropriate and discuss your potential risks and benefits, advises Dr. Schmidt. More effective weight loss medications are available for your consideration, if weight loss is your primary goal.
'All in all, metformin remains a reliable option for managing blood sugar and may offer some additional metabolic benefits. It may help with some weight loss, but it's no magic pill; it works best when paired with healthy lifestyle changes,' adds Dr. Setareh.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Incyte replaces CEO Hoppenot with dealmaker Meury
Incyte replaces CEO Hoppenot with dealmaker Meury

Yahoo

time39 minutes ago

  • Yahoo

Incyte replaces CEO Hoppenot with dealmaker Meury

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Incyte has named veteran pharmaceutical executive Bill Meury as its new CEO, replacing longtime head Hervé Hoppenot, who led the cancer and blood disease drugmaker for the past 11 years. Meury, whose appointment is effective immediately, previously ran Anthos Therapeutics, which he sold this year to Novartis for nearly $1 billion, and Karuna Therapeutics, which Bristol Myers Squibb bought for $14 billion in 2023. Prior to those posts, Meury was chief commercial officer at Allergan. Hoppenot will remain on Incyte's board of directors through the end of this year to aid Meury's transition into the CEO role. Alongside the succession, Julian Baker, managing partner of biotechnology investor Baker Bros. Advisors and lead independent director for Incyte, was elected board chair. Much of Hoppenot's time at Incyte focused on what he once described as 'single asset syndrome.' The company has had a good deal of success with Jakafi, a multipurpose drug approved to treat rare blood cancers and graft-versus-host disease. Last year, Jakafi brought in nearly $2.8 billion in sales. But Jakafi's main patents expire in 2028, a date that for years now has been on investors' radar as they've pressed Incyte on what it expects will take the drug's place. Early in Hoppenot's tenure, the answer looked like a cancer medicine called epacadostat, which Incyte believed could become a cornerstone of immunotherapy combinations. However, it flamed out in testing in 2018 and Incyte was forced to pivot research toward other candidates. Since then, Incyte has had some success building out its portfolio. The company now owns six other approved drugs, including a cream formulation of Jakafi's main ingredient that's proved useful treating atopic dermatitis and vitiligo. 'Hervé joined Incyte in 2014 when it was a single product, U.S.-only company,' said board member Baker, in a statement. 'During Hervé's tenure, Incyte launched six novel medicines plus two new indications for Jakafi, expanded commercial operations into Europe, Japan and Canada and grew revenues from $355 million dollars in 2013 to $4.2 billion today.' However, Incyte's other drugs don't make it much money. Jakafi and the cream formulation of the drug Incyte sells as Opzelura accounted for 91% of net product revenues last year. (The company also earned nearly $600 million in royalty revenues.) Stephen Willey, an analyst at Stifel, gives Hoppenot credit for increasing Incyte revenues by more than 10 times during his time as CEO. But, in a Thursday note to clients, he added that some investors grew frustrated with the company's high research and development spending without a clear post-Jakafi plan. Shaping those plans will now fall to Meury, who gained industry visibility by guiding his prior two companies to lucrative acquisitions. 'We expect the immediate reaction from investors will be an expectation that [Incyte] could now become an M&A target, simply because Mr. Meury sold Anthos ... and sold [Karuna],' wrote RBC Capital Markets analyst Brian Abrahams, in a note to clients. Shares in Incyte, which have fallen by 30% over the past five years, rose by more than 4% in Thursday morning trading on the CEO news. 'It has been a privilege to lead Incyte over the past eleven years,' Hoppenot said in the company's statement. 'I am proud to retire at a time when Incyte has the strongest management team, internal R&D pipeline and commercial portfolio ever.' Incyte expects multiple pivotal trial readouts this year, along with proof-of-concept data for several pipeline candidates. Recommended Reading Unblinded: Hervé​ Hoppenot on solving Incyte's 'single asset syndrome' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

After tearing his ACL, a Pennsylvania high school athlete received a new kind of treatment that avoids re-rupture
After tearing his ACL, a Pennsylvania high school athlete received a new kind of treatment that avoids re-rupture

CBS News

timean hour ago

  • CBS News

After tearing his ACL, a Pennsylvania high school athlete received a new kind of treatment that avoids re-rupture

New medical technology being used to reduce the risk of repeat injuries suffered by athletes New medical technology being used to reduce the risk of repeat injuries suffered by athletes New medical technology being used to reduce the risk of repeat injuries suffered by athletes A new medical technology that acts like a seatbelt is aimed at reducing the risk of repeated knee injuries often suffered by athletes of all levels. Seventeen-year-old Nicholas Pohorilenko is ready to start practice after tearing his ACL almost two years ago. "Honestly, I thought my like sports career was over because a lot of people don't come back from that," Pohorilenko said. The tight end for Council Rock South High School said it happened when another player's helmet crashed into his knee. "I was able to jog off the field, and then I got to the sidelines and I like literally couldn't walk," he said, "It was horrible." The ACL –anterior cruciate ligament – is a vital structure in the knee. A tear or rupture requires surgery and a long rehab. "Our young athletes who, in general, have the highest rate of ACL injury also, unfortunately, come with the highest rates of re-rupture," said Dr. Sommer Hammoud with Rothman Orthopaedics. Dr. Hammoud is using new technology to reduce the risk of a potential re-rupture. She said it's like a seatbelt that's surgically implanted with the graft, which is used to repair the ACL. It prevents the graft from being overstretched, acting like an internal brace. Arthrex "I think this is the simplest thing that one can add to a ligament repair or reconstruction that is likely gonna have a huge potential benefit to the patient," said Dr. Hammoud. Pohorilenko said the rehab was long and difficult, but he's happy he has the so-called seatbelt in his repaired knee. "I think it's great, like, cause you people tear their ACLs multiple, multiple times," he said. "With this, tear it once, you get this technology and you're done." Best of all, his knee is fine and he'll be back playing the game he loves for his senior season. Since the technology is relatively new, doctors don't know yet exactly how much it will reduce re-ruptures of the ACL. CBS Philadelphia

Angels manager Ron Washington to miss rest of season with unspecified medical issue
Angels manager Ron Washington to miss rest of season with unspecified medical issue

Washington Post

timean hour ago

  • Washington Post

Angels manager Ron Washington to miss rest of season with unspecified medical issue

ANAHEIM, Calif. — Los Angeles Angels manager Ron Washington will miss the rest of the season because of an unspecified medical issue, the team said Friday. Washington, the oldest manager in the major leagues at 73, has been sidelined for the past week. He experienced shortness of breath and appeared fatigued toward the end of a four-game series at the New York Yankees that ended on June 19. He flew back to Southern California, underwent a series of tests and was placed on medical leave.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store